Format

Send to

Choose Destination

See 1 citation found by title matching your search:

Eur J Pediatr. 2012 Sep;171(9):1339-48. doi: 10.1007/s00431-012-1726-4. Epub 2012 Apr 29.

Hereditary angioedema (HAE) in children and adolescents--a consensus on therapeutic strategies.

Author information

1
Department of Pediatric Pneumology and Immunology, Campus Virchow Hospital, Charité Medical University, Augustenburger Platz 1, 13353 Berlin, Germany. Volker.Wahn@charite.de

Abstract

Hereditary angioedema due to C1 inhibitor (C1 esterase inhibitor) deficiency (types I and II HAE-C1-INH) is a rare disease that usually presents during childhood or adolescence with intermittent episodes of potentially life-threatening angioedema. Diagnosis as early as possible is important to avoid ineffective therapies and to properly treat swelling attacks. At a consensus meeting in June 2011, pediatricians and dermatologists from Germany, Austria, and Switzerland reviewed the currently available literature, including published international consensus recommendations for HAE therapy across all age groups. Published recommendations cannot be unconditionally adopted for pediatric patients in German-speaking countries given the current approval status of HAE drugs. This article provides an overview and discusses drugs available for HAE therapy, their approval status, and study results obtained in adult and pediatric patients. Recommendations for developing appropriate treatment strategies in the management of HAE in pediatric patients in German-speaking countries are provided.Conclusion Currently, plasma-derived C1 inhibitor concentrate is considered the best available option for the treatment of acute HAE-C1-INH attacks in pediatric patients in German-speaking countries, as well as for short-term and long-term prophylaxis.

PMID:
22543566
PMCID:
PMC3419830
DOI:
10.1007/s00431-012-1726-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Springer Icon for PubMed Central
Loading ...
Support Center